Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study.

Nadya J Jammal Yifang Eva PanMichael HurwitzRebecca B Abramovitz

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Based on this review, it appears that combination tyrosine kinase inhibitors/immune checkpoint inhibitors therapy in pre-treated patients with mRCC is tolerable and beneficial.

Keyphrases

combination therapy
metastatic renal cell carcinoma
chronic myeloid leukemia
stem cells
skeletal muscle
mesenchymal stem cells
weight loss